Nurix Therapeutics, Inc. (NRIX)

Market Cap	401.02M
Revenue (ttm)	60.94M
Net Income (ttm)	-157.44M
Shares Out	48.20M
EPS (ttm)	-2.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	335,046
Open	8.53
Previous Close	8.52
Day's Range	8.26 - 8.67
52-Week Range	8.12 - 15.09
Beta	1.61
Analysts	Strong Buy
Price Target	27.56 (+231.25%)
Earnings Date	Oct 9, 2023

About NRIX

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casita...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 2020
• Employees: 297
• Stock Exchange: NASDAQ
• Ticker Symbol: NRIX

Financial Performance

In 2022, NRIX's revenue was $38.63 million, an increase of 29.84% compared to the previous year's $29.75 million. Losses were -$180.36 million, 53.9% more than in 2021.

Analyst Forecast

According to 9 analysts, the average rating for NRIX stock is "Strong Buy." The 12-month stock price forecast is $27.56, which is an increase of 231.25% from the latest price.

Price Target

$27.56

(231.25% upside)

Analyst Consensus: Strong Buy